Patents Assigned to N.V. Organon
-
Publication number: 20070299268Abstract: Process for the preparation of a compound of general formula (II) wherein R1 and R2 independently are hydrogen or a hydroxy- or hydrocarbyl group; or wherein R1 and R2 together are a double bonded oxygen; R3 is hydrogen; R?4 is a nitrobenzophenone none group; and R5 and R6 independently are hydrogen or a hydroxy- or hydrocarbyl group; from a compound of general formula (I) wherein, R1, R2 R3, R5 and R6 are as defined above and R4 is hydrogen; wherein the compound of formula (I) is reacted under alkaline conditions with 2-chloro-5-nitrobenzophenone in the presence of an alkanolic solvent and the compound of formula (II) is directly crystallized from this alkanolic solvent. Complex of an alkanol and a compound of general formula (II) obtainable from the above process and processes wherein the above process or complex are used.Type: ApplicationFiled: August 22, 2005Publication date: December 27, 2007Applicant: N.V. OrganonInventors: Lambertus Gerardus Willems, Henricus Johannes Maas, Martin Ostendorf
-
Publication number: 20070299035Abstract: The invention relates to the use of chemical chelators for the preparation of a medicament for the reversal of drug-induced neuromuscular block, to a kit for providing neuromuscular block and its reversal, and to cyclophane derivatives having the general formula A wherein R is the general formula B wherein X is or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 19, 2007Publication date: December 27, 2007Applicant: N.V. OrganonInventors: Antonius Bom, Alan Muir, David Rees
-
Patent number: 7307073Abstract: The present invention relates to benzoxazepine derivative having the general formula I, wherein X represents CO or SO2; R1, R2, R3 and R4 are independently selected from H, (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkyloxy(C1-4)alkyl, halogen, nitro, cyano, NR8R9, NR8COR10, and CONR8R9, R5, R6 and R7 are independently H or (C1-4)alkyl; R8 and R9 are independently H or (C1-4)alkyl; or R8 and R9 form together with the nitrogen atom to which they are bound a 5- or 6-membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O, S or NR11; R10 is (C1-4)alkyl; R11 is (C1-4)alkyl; A represents the residue of a 4-7 membered saturated heterocyclic ring, optionally containing an oxygen atom, the ring being optionally substituted with 1-3 substituents selected from (C1-4)alkyl, (C1-4)alkyloxy, hydroxy, halogen and oxo; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 5, 2002Date of Patent: December 11, 2007Assignee: N.V. OrganonInventors: Simon James Anthony Grove, Mingqiang Zhang, Mohammad Shahid
-
Patent number: 7304155Abstract: A compound having the formula I wherein the O—(CH2)n—N(R1,R2) substituent on the phenyl ring can be in meta or para position; n is 2-4 Re and ?Re are OH, optionally independently etherified or esterified; R1 and R2 are independently (1C-4C)alkyl, (2C-4C)alkenyl, hydroxy(2C-4C)alkyl, (1C-3C)alkoxy(2C-4C)alkyl, aryl or aryl(1C-2C)alkyl; or R1 and R2 together with the nitrogen form an aromatic or non-aromatic heterocyclic ring structure, optionally mono- or poly-substituted with (1C-4C)alkyl, (2C-4C)alkenyl, hydroxy(1C-2C)alkyl, (1C-2C)alkoxy(1C-3C)alkyl or aryl. These compounds can be used for estrogen receptor ? selective medical treatments.Type: GrantFiled: December 16, 2002Date of Patent: December 4, 2007Assignee: N.V. OrganonInventor: Hubert Jan Jozef Loozen
-
Patent number: 7304064Abstract: The present invention relates to 1-[(indol-3-yl)carbonyl]piperazine derivative according to the general formula I or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said 1-[(indol-3-yl)carbonyl]piperazine derivatives, and to the use of these derivatives in the treatment of pain, such as peri-operative pain, chronic pain neuropathic pain, cancer pain, and pain and spasticity associated with multiple sclerosis.Type: GrantFiled: June 13, 2003Date of Patent: December 4, 2007Assignee: N.V. OrganonInventors: Phillip Martin Cowley, Wilson Caulfield, Jason Tierney, James Cairns, Julia Adam-Worrall, Mark York
-
Publication number: 20070270413Abstract: This invention relates to a method of treatment of neuropathic pain comprising administering to a subject in need of treatment for neuropathic pain a therapeutically effective dose of S(+)-mirtazapine and the use of S(+)-mirtazapine for the manufacture of a medicine for the treatment of neuropathic pain and a pharmaceutical composition for the treatment of neuropathic pain, comprising S(+)-mirtazapine.Type: ApplicationFiled: May 17, 2007Publication date: November 22, 2007Applicant: N.V. OrganonInventors: Andrea Houghton, Gerardus Stephanus Franciscus Ruigt
-
Publication number: 20070265245Abstract: The invention provides a method of treatment of hot flush with S-mirtazapine and the use of S-mirtazapine for the manufacture of a medicament for the treatment of hot flush.Type: ApplicationFiled: November 14, 2005Publication date: November 15, 2007Applicant: N.V. OrganonInventors: Bernardus Wijnand Mathys Marie Peeters, Anton Adang
-
Publication number: 20070254860Abstract: The invention provides 15?-substituted steroidal compounds having selective estrogen receptor activity according to Formula (I) wherein, R1 is H, C1-5 alkyl, C1-12 acyl, di-(C1-5 alkyl)aminocarbonyl, (C1-5alkyl)oxycarbonyl or sulfamoyl, R2 is H, C1-3alkyl, C2-3alkenyl or C2-3alkynyl, each of which may be optionally substituted with a halogen, R3 is C1-2alkyl, ethenyl or ethynyl, each of which may be optionally substituted with a halogen, and R4 is H or C1-12 acyl.Type: ApplicationFiled: September 5, 2005Publication date: November 1, 2007Applicant: N.V. OrganonInventors: Hubert Jan Loozen, Antonius Gerardus Ederveen, Fredericus Dijcks
-
Patent number: 7279305Abstract: A newly identified gene, DIS1 is disrupted by a (1;11)(q42.1;q14.3) translocation which segregates with schizophrenia. We have examined the genomic structure of DIS1 and found that the gene consists of 13 exons estimated to extend across at least 300 kb of DNA. Exon 11 contains an alternative splice site which removes 66 nucleotides from the open reading frame. The final intron of DIS1 belongs to the rare AT-AC class of introns. 8 expressed sequence tags (ESTs) located within introns 3, 7, 9 and 10 of DIS1 have also been identified. These ESTs have not yet been assigned to DIS1 and may therefore represent further novel genes in the region.Type: GrantFiled: November 28, 2000Date of Patent: October 9, 2007Assignee: N.V. OrganonInventors: David Porteous, Kirsty Millar, Douglas Blackwood, Walter John Muir
-
Publication number: 20070208002Abstract: The invention provides a method to effectively wean a woman from hormonal therapy for treatment of vasomotor symptoms by reducing the dosage of the hormonal agent to zero, while a non-hormonal drug in an amount, which is therapeutically effective for treating vasomotor symptoms, is administered or initiated and continued for one or more periods of durations determined by assessment of the effect of a treatment free period, which follows each period of continuous non-hormonal drug treatment.Type: ApplicationFiled: March 6, 2007Publication date: September 6, 2007Applicant: N.V. OrganonInventors: Edward Baker, Simon Johannes van den Berg
-
Publication number: 20070203105Abstract: The subject invention provides a compound according to Formula I, wherein each of the substituents is given the definition as set forth in the specification and claims, or a pharmaceutically acceptable salt and/or hydrate form and/or prodrug thereof.Type: ApplicationFiled: March 18, 2005Publication date: August 30, 2007Applicant: N.V. OrganonInventors: Johannes Antonius Maria Hamersma, Johannes Bernardus Maria Rewinkel
-
Publication number: 20070197527Abstract: A bicyclic heteroaromatic compound according to general formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, (6-14C)aryl or (4-13C)heteroaryl; all optionally substituted with one or more substituents; R2 is (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (6-14C)aryl or (4-13C)heteroaryl; R3 is (1-8C)alkyl, (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, (6-14C)aryl or (4-13C)heteroaryl; Y is CH or N; Z is NH2 or OH; A is S, N(H), N(R), O or a bond and B is N(H), O or a bond; X1-X2 is C?C, C(O)—NH, NH—C(O), C(O)—O, O—C(O), C?N, N?C or S or O. The compounds of the invention can be used in fertility regulation therapies.Type: ApplicationFiled: April 23, 2007Publication date: August 23, 2007Applicant: N.V. OrganonInventors: Cornelis Timmers, Willem Karstens
-
Publication number: 20070185156Abstract: The present invention relates to a 8-azabicyclo[3.2.1]octane derivative of Formula I, wherein each of the substituents is given the definition as set forth in the specification and claims, or a pharmaceutically acceptable salt thereof or solvate thereof. The present invention also relates to a pharmaceutical composition comprising an 8-azabicyclo[3.2.1]octane derivative in admixture with one or more pharmaceutically acceptable auxiliaries and to the use of the 8-azabicyclo[3.2.1]octane derivative in therapy.Type: ApplicationFiled: December 1, 2006Publication date: August 9, 2007Applicant: N.V. OrganonInventors: Susan Napier, Matilda Bingham, Neil Dunbar
-
Patent number: 7252934Abstract: Interaction of Rel proteins and steroid receptors is known to result in repression of target genes. Here we describe the discovery of a new mechanism in which Rel proteins and steroid receptors act synergistically to activate a regulatory element. This mechanism is shown to influence the expression of the brain-specific 5HT1A receptor wherein the estrogen receptor acts synergistically with the Nuclear Factor kappa B to enhance the activity of the promoter for the 5HT1A receptor gene. In addition, synergistic effects of Rel proteins with the mineralocorticoid receptor were observed, showing that synergism with Rel proteins may be expected for other steroid receptors as well. The synergism between Rel proteins and estrogen receptor or mineralocorticoid receptor provides a tool for the development of compounds that interact with the estrogen or mineralocorticoid receptor in such a way that only the synergistic effect is modulated whereas other effects are left intact.Type: GrantFiled: March 6, 2001Date of Patent: August 7, 2007Assignee: N.V. OrganonInventors: Christine J. C. Boersma, Paulus Theodorus Maria Van Der Saag, Sacha Wissink, Bart Van Der Burg
-
Publication number: 20070179138Abstract: The present invention relates to 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives having the general Formula I wherein each of the substituents is given the definition as set forth in the specification and claims, pharmaceutical compositions comprising the same as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S and/or cathepsin K related diseases such as osteoporosis, atherosclerosis, inflammation and immune disorders, such as rheumatoid arthritis, and chronic pain, such as neuropathic pain.Type: ApplicationFiled: January 16, 2007Publication date: August 2, 2007Applicant: N.V. OrganonInventors: Jiaqiang Cai, Zoran Rankovic, Philip Jones, David Bennett, Iain Cumming, Jonathan Gillespie
-
Publication number: 20070178550Abstract: The invention relates to an isolated polynucleotide sequence comprising a nucleic acid sequence encoding the amino acid sequence of KshA protein or of KshB protein, encoded by nucleotides 499-1695 of SEQ ID NO:1 or by nucleotides 387-1427 of SEQ ID NO:2, respectively, and functional homologues thereof. The polynucleotides of the invention can be used to construct genetically modified microorganisms blocked in 3-ketosteroid 9?-hydroxylase activity, which are useful in the microbial degradation of steroids to accumulate certain steroid products.Type: ApplicationFiled: April 3, 2007Publication date: August 2, 2007Applicant: N.V. OrganonInventors: Robert Van Der Geize, Peter Van Der Meijden, Gerda Hessels, Lubbert Dijkhuizen
-
Publication number: 20070149577Abstract: The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R1 is hydrogen, halogen, CN or (1C-4C)alkyl; R2 is hydrogen, halogen or optionally fluorinated (1C-3C)alkoxy; R3 and R5 are independently hydrogen, optionally halogenated (1C-4C)alkyl, optionally halogenated (1C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1C-4C)alkenyl or hydroxylmethyl; R4 is hydrogen, halogen, optionally halogenated (1C-4C)alkoxy or optionally halogenated aryl(1C-4C)alkoxy; R6 is hydrogen, benzyl, optionally substituted with one or more halogens or (1C-4C)alkyl, or R6 is optionally halogenated (1C-4C)alkyl; each R7 independently is hydrogen, halogen, optionally halogenated (1C-4C)alkyl or optionally halogenated (1C-4C)alkoxy and pharmaceutically suitable acid addition salts thereof for use as glucocorticoid receptor modulators, in particular for treatment of central nervous system disorders.Type: ApplicationFiled: December 19, 2006Publication date: June 28, 2007Applicants: N.V. Organon, Pharmacopeia Drug Discovery Inc.Inventors: Niall Hamilton, Simon Grove, Michael Kiczun, John Morphy, Brad Sherborne, Peter Littlewood, Angus Brown, Celia Kingsbury, Michael Ohlmeyer, Koc-Kan Ho, Steven Kultgen
-
Publication number: 20070141102Abstract: Disclosed herein is a drug delivery system consisting of one or more compartments and comprising a progestogenic compound dissolved in a thermoplastic polyethylene vinylacetate copolymer. Also disclosed are a contraceptive kit or hormone-replacement therapy kit comprising the drug delivery system, and a combination preparation that simultaneously provides contraception and treatment of a sexually transmitted disease comprising the drug delivery system.Type: ApplicationFiled: March 16, 2005Publication date: June 21, 2007Applicant: N.V. ORGANONInventors: Wouter De Graaff, Janneke Groen, Marcus Antonius Kruft, Johannes Antonius Van Laarhoven, Herman Vromans, Raymond Zeeman
-
Publication number: 20070135479Abstract: The invention relates to isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 1 or 2; R1 is H, when Y is NH2; or R. is H, (C1-4)alkyl or halogen, when Y is OH; R2 and R3 are independently H, (C1-4)alkyl or halogen; R is H or (C1-6)alkyl, optionally substituted with OH, (C1-4)-alkyloxy, (C1-4)alkyloxycarbonyl, (C3-7)cycloalkyl, which may optionally comprise a heteroatom selected from O and S, (C6-10)aryl, (C6-10)aryloxy or a 5- or 6-membered heteroaryl group comprising 1-3 heteroatoms independently selected from O, N and S, each aryl or heteroaryl group being optionally substituted with 1-3 substituents independently selected from (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkylsulfonyl and halogen; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same as well as to the use of the isoquinoline derivatives in the treatment of ROCK-I related disorders such as hypertension, atherosclerosis and glaucoma.Type: ApplicationFiled: December 5, 2006Publication date: June 14, 2007Applicant: N.V. OrganonInventor: Peter Ray
-
Patent number: D551759Type: GrantFiled: November 3, 2005Date of Patent: September 25, 2007Assignee: N. V. OrganonInventors: Maurice Petrus Wilhelmus Tak, Iris Epkjen Hobo-V. D. Graaf